Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2010

View Archived Issues

ENB-0040 shows promise to treat hypophosphatasia in children

Serodus identifies new serotonin 5-HT4 receptor antagonists

AMG-386 is active in renal cell carcinoma and ovarian cancer

Panobinostat has antitumor activity in phase II trial in SCLC

Adjuvanted VZV subunit vaccine gE/AS01B is more immunogenic than Varilrix

CMX-001 effective in immunocompromised adenovirus-infected patients

Pradaxa arrives in U.S. pharmacies

Primary endpoint met in phase III HPN-100 trial in urea cycle disorders

Incyte begins global phase III INCB-18424 trial in polycythemia vera

Shire presents new prodrugs of opioids for the treatment of pain

Phase III data reported on linaclotide in IBS with constipation

New ligands of glucocorticoid receptors disclosed by AstraZeneca

RegeneRx Biopharma reports preclinical data on RGN-259 for dry eye syndrome

New metabotropic glutamate mGlu2 receptor agonists claimed

CeNeRx BioPharma presents safety data on new CX-157 formulation

Medicago's H5N1 avian flu vaccine approved to enter phase II trial

New beta-secretase 1 inhibitors patented

FDA approves Teflaro for CABP and ABSSSI in adults

Soligenix presents preliminary phase Ib safety data on RiVax

BC-819 shows good safety profile in phase I/IIa trial in pancreatic cancer

MabThera approved in E.U. as maintenance treatment of follicular lymphoma

Viralytics submits IND for phase II trial of Cavatak in melanoma

Phase II CD-NP trial in acute decompensated heart failure meets endpoint

Gynecologic Oncology Group to begin phase II elesclomol trial in ovarian cancer

FDA extends review of BMS' BLA for ipilimumab in advanced melanoma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...